Mar 24,2022

Abbott Diabetes Care Diabetes Care'S FREESTYLE® LIBRE IS FIRST AND ONLY CGM SYSTEM TO GAIN EXPANDED REIMBURSEMENT IN JAPAN TO INCLUDE ALL PEOPLE WITH DIABETES WHO USE INSULIN

Abbott Diabetes Care Diabetes Care (NYSE: ABT) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle® Libre system to include all people with diabetes who use insulin at least once a day.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 25,2022

BD Named One of America's Most Trusted Companies by Newsweek

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted Companies " in the Health Care and Life Sciences category.

View Analyst & Ambassador Comments
Go to original news
Mar 25,2022

Dexcom Announces Four-for-One Forward Stock Split

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock.

View Analyst & Ambassador Comments
Go to original news
Mar 25,2022

MicroTech Medical Inc：Announcements and Notices - [Final Results]ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021

MicroTech Medical (Hangzhou) Co., Ltd. is pleased to announce the audited consolidated annual results of the Company and its subsidiaries for the year ended December 31, 2021,

View Analyst & Ambassador Comments
Go to original news
Mar 26,2022

Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study

This study examined the durability of continuous glucose monitoring (CGM) coupled with a family behavioral intervention (FBI) to improve glycemia.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 26,2022

Determining Losses in Jet Injection Subcutaneous Insulin Delivery: A Model-Based Approach

This study employs model-based methods to determine the expected proportion of active insulin present from a needle-free jet injectors.

CLINICAL STUDY

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Mar 28,2022

Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced its financial results for the fourth quarter and full year ending December 31, 2021.

View Analyst & Ambassador Comments
Go to original news
Mar 28,2022

Abbott Diabetes Care Diabetes Care HOSTS CONFERENCE CALL FOR FIRST-QUARTER EARNINGS

Abbott Diabetes Care Diabetes Care (NYSE: ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens.

View Analyst & Ambassador Comments
Go to original news
Mar 29,2022

Owens & Minor, Inc. Completes Acquisition of Apria, Inc.

Owens & Minor, a leading global healthcare solutions company, today announced that it has closed the previously announced acquisition of Apria, Inc. The acquisition was consummated for total consideration in cash of approximately $1.6 billion. Apria will be combined with Owens & Minor’s existing Byram Healthcare business to form the new Patient Direct segment. This new segment creates a robust commercial team with greater access to patients across a wider geographic footprint. It also expands Owens & Minor’s home healthcare portfolio to cover an unmatched range of chronic and acute care needs including diabetes, ostomy, incontinence, wound care, home respiratory, obstructive sleep apnea and negative pressure wound therapy.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Mar 29,2022

Innit Unveils Joint Solutions With Google Cloud for Health and Wellness

Innit, an innovator in personalized food technology, announced an expansion of its strategic partnership with Google Cloud, launching joint health and wellness solutions to support healthy eating for a range of conditions such as diabetes, hypertension, obesity, and heart disease.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES